How, Jeffrey A. http://orcid.org/0000-0003-1446-9574
Jazaeri, Amir A. http://orcid.org/0000-0003-4335-4151
Soliman, Pamela T.
Fleming, Nicole D.
Gong, Jing
Piha-Paul, Sarina A.
Janku, Filip http://orcid.org/0000-0002-8123-4065
Stephen, Bettzy http://orcid.org/0000-0003-1653-2012
Naing, Aung http://orcid.org/0000-0002-4803-8513
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (T32 CA101642 JH, P30CA016672)
Dr. Henry R. Shibata Fellowship Award/Cedars Cancer Foundation
Merck
Article History
Received: 13 October 2020
Accepted: 26 January 2021
First Online: 11 February 2021
Competing interests
: Jeffrey How reports grants from NIH (T32 CA101642) and the Cedars Cancer Foundation during the conduct of the study. Amir Jazaeri reports personal fees from Gerson and Lehrman Group, Guidepoint, Iovance Advisory Board Meeting, Nuprobe, Simcere, and Pact Pharma outside the submitted work. He reports grants from AstraZenea, BMS, Iovance, Aravive, Pfizer, Immatics USA, and Eli Lilly outside the submitted work. He reports conference traveling fees from AstraZeneca outside the submitted work. Pamela Soliman reports research grant funding from Novartis and Incyte for outside the submitted work. Nicole Fleming reports personal fees from Tesaro, BMS, and Pfizer Advisory Boards outside the submitted work. Sarina A. Piha-Paul receives research/grant funding from outside the submitted work and include AbbVie, ABM Therapeutics, Acepodia, Alkermes, Aminex Therapeutics, Amphivena Therapeutics, BioMarin Pharmaceutical, Boehringer Ingelheim, Bristol Myers Squib, Cerulean Pharma, Chugai Pharmaceutical Co, Curis, Daichi Sanko, Eli Lilly, ENB Therapeutics, Five Prime Therapeutics, Gene Quantum, Genmab A/S, GlaxoSmithKline, Helix BioPharma Corp, Incyte Corp, Jacobio Pharmaceuticals Co, Medimmune LLC, Medivation, Merck Sharp and Dohme Corp, Novartis Pharmaceuticals, Pieris Pharmaceuticals, Pfizer, Principia Biopharma, Inc, Puma Biotechnology, Rapt Therapeutics, Seattle Genetics, Silverback Therapeutics, Taiho Oncology, Tesaro, TransThera Bio, and NCI/NIH; P30CA016672—Core Grant (CCSG Shared Resources) outside submitted work. Filip Janku reports grants from Novartis, Gentech, BioMed Valley Discoveries, Plexxikon, Deciphera, Piqur, Symphogen, Bayer, FujiFilm Corporation and Upsher-Smith Laboratories, Astex, Asana, Astellas, Agios, Proximagen, Bristol-Myers Squibb, and IFM Therapeutics. He reports personal fees from Synlogic, Guardant Health, Ideaya, PureTech Health, Trovagene, Immunomet, Jazz Pharmaceuticals, and Sotio, outside the submitted work. Aung Naing reports grants from NCI, EMD Serono, MedImmune, Healios Onc. Nutrition, Atterocor/Millendo, Amplimmune, ARMO BioSciences, Karyopharm Therapeutics, Incyte, Novartis, Regeneron, Merck, Bristol-Myers Squibb, Pfizer, CytomX Therapeutics, Neon Therapeutics, Calithera Biosciences, TopAlliance Biosciences, Eli Lilly, Kymab, PsiOxus, Arcus Biosciences, NeoImmuneTech, ImmuneOncia, and Surface Oncology. He is on the advisory board for CytomX Therapeutics, Novartis, Genome & Company, OncoSec KEYNOTE-695, Kymab, and STCube Pharmaceuticals. He has received travel and accommodation expenses from ARMO BioSciences. Aung Naing’s spouse receives research funding from Immune Deficiency Foundation, Jeffery Modell Foundation and chao physician-scientist, and Baxalta. She is also on the advisory board for Takeda, CSL, Behring, Horizon, and Pharming. Jing Gong and Bettzy Stephen have nothing to disclose.